Chronic Myelomonocytic Leukemia Survival Rate by Age

Chronic myelomonocytic leukemia, or CMML, is a rare blood cancer that mostly appears in people in their 70s. For most of them it shortens life to a matter of a few years rather than decades.1PubMed. Incidence and survival of chronic myelomonocytic leukemia in Girona (Spain): a population-based study, 1993-2007 Age is only one part of the picture, though, and survival ranges widely from person to person even at the same age. Younger patients live longer overall, yet they also face a higher chance of the disease turning into acute leukemia.

Typical CMML Survival at Different Ages

Survival figures are usually given as a “median,” the point at which half of patients are still alive and half are not. These are the numbers most patients will hear:

Older groups look so much lower partly because they include frail people who cannot have strong treatment, and because some deaths come from heart disease or other illness rather than the leukemia. The younger figures come from specialist centres, which may see fitter patients.

Risk of death climbs with age. Compared with younger adults, people aged 60 to 79 had nearly twice the risk of dying during follow-up.7PubMed Central. Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database People 80 and older had close to three times the risk, and in some analyses more than three times.8PubMed Central. Survival Outcomes of U.S. Patients with CMML: A Two-Decade Analysis from the SEER Database Part of that rise comes from other illnesses common in older age, not only the leukemia.

A median is a midpoint, so a figure like 13 months does not mean most people die near that date. The spread around it is wide, with some people living only a few months and others many years. Someone who has already lived well past diagnosis often has a better outlook than the original figure suggests, since the early deaths in the group no longer apply to them.

The figures also describe people diagnosed years ago, before some current treatments, so people diagnosed today may do somewhat differently. Your doctor’s estimate uses your own blood counts, not just your age. Ask for the figure for people with your risk group and counts.

What Besides Age Shapes Your Outlook

Doctors score risk using age over 65, a white blood cell count above 15 (×10⁹/L), platelets below 100, and anemia.9PubMed. Prognostic score including gene mutations in chronic myelomonocytic leukemia Anemia here means hemoglobin below 10 g/dL in women or below 11 g/dL in men.10PubMed. Prognostic score including gene mutations in chronic myelomonocytic leukemia You can find hemoglobin, white count, and platelets on your blood count printout. A gene change called ASXL1 also counts against survival, so ask whether your bone marrow was tested for it.11PubMed. Prognostic score including gene mutations in chronic myelomonocytic leukemia In younger patients, SRSF2 changes and a higher share of blasts, immature blood cells, in the blood also lowered survival.12Nature / Blood Cancer Journal. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome

Each risk factor adds to a tally, and the total places a person in a lower, intermediate or higher risk group. That is why your doctor may name a group instead of quoting a single number. A person with no risk factors sits in the lowest group, while someone with several sits in a higher one, with clearly different expected survival between them. The groups guide decisions such as whether to watch and wait, start treatment, or discuss transplant. Several scoring systems exist and weigh features a little differently, so it is reasonable to ask which one your team used. Because counts change over time, the score is rechecked.

Your diagnosis may say CMML-1 or CMML-2, depending on how many immature cells are found.13Nature / Blood Cancer Journal. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome Check which one your pathology report states. Among younger adults, median survival was 59 months with CMML-1 but 24 months with CMML-2.14Blood Cancer Journal. Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome Abnormal chromosomes in the leukemia cells are more common in older patients and come with worse counts.15PubMed. Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study

CMML is also split into a type with low counts and one with high white counts and an enlarged spleen.16PubMed. Problems in the classification of CMML–dysplastic versus proliferative type The high-count type has been linked to shorter survival in one group, about 11 versus 30 months.17PubMed. Myelodysplastic and myeloproliferative type of chronic myelomonocytic leukemia–distinct subgroups or two stages of the same disease? Other doctors found the split made little difference to survival, so treat it as one clue among several.18PubMed. Problems in the classification of CMML–dysplastic versus proliferative type

Mutation testing is worth asking about. It looks at the DNA of the abnormal marrow cells and is done on a bone marrow or blood sample, so it often needs to be requested or confirmed rather than assumed. A result such as ASXL1 or SRSF2 can move you into a different risk group even when your counts look similar to someone else’s. Results can also help confirm the diagnosis when marrow findings are borderline, and they can open the door to trials aimed at specific features of the disease.

Other Health Problems and Life Circumstances

A standard count of other long-term illnesses predicted survival better than more specialised checklists.19PubMed. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study Autoimmune conditions also turn up more often in people with CMML.20PubMed. Prognostic scoring systems and comorbidities in chronic myelomonocytic leukaemia: a nationwide population-based study

Those illnesses change what treatment is possible. Heart failure, lung disease, kidney problems and poorly controlled diabetes can limit which drugs a person can safely take and how well they tolerate low blood counts. Anemia from CMML can make existing heart or lung disease feel worse, so the two are best treated together. Some medicines for other conditions can interact with cancer treatments or affect blood counts. Well-controlled conditions can keep a person eligible for treatments, including transplant in some fit older patients.

For the first haematologist visit, bring a list of all diagnoses and medicines. Mention past autoimmune problems such as arthritis or thyroid disease. Fitness and independence affect which treatments are offered, so describe how you manage day to day.

Treatment at an academic cancer centre was linked to longer survival.21PubMed. Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis Medicaid coverage and low-income neighbourhoods were linked to shorter survival in the US.22PubMed. Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis Women tended to live longer than men, and Black patients had shorter survival.23PubMed. Chronic Myelomonocytic Leukemia and Atypical Chronic Myeloid Leukemia: A National Analysis

These associations do not mean income or insurance causes shorter survival in any one person. They may reflect later diagnosis, other illnesses or less access to treatment. Asking for at least one opinion from a centre that sees CMML is worthwhile, and travel can often be eased by a one-time consultation, with ongoing care closer to home.

How Treatment Changes Survival at Different Ages

Azacitidine is a drug given as injections or infusions for several days each month, and it is now the most used treatment.24PubMed Central. Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia It changes how genes in the abnormal blood cells are switched on and off rather than killing cells outright. Older US patients diagnosed after it arrived lived a median 17 months versus 11 months before.25PubMed Central. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study Only about 4 in 10 people respond to it noticeably, though.26PubMed Central. 5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature

In practice, it means several days of shots each month at a clinic, usually about a week per cycle, and treatment generally continues as long as it is helping and being tolerated, which may be many months or longer. It is not a cure; the aim is to improve blood counts, reduce transfusions and slow the disease.

Blood counts often get worse before they improve, because the drug also affects healthy marrow cells, so the early weeks can be rough. Doctors usually wait several cycles, often around four to six, before judging whether it is working. Common side effects include low counts, tiredness, nausea and redness or bruising where the injection was given, and teams can often ease them. A fever during treatment needs a prompt call, since low white counts make infections more serious.

Hydroxyurea, a tablet, brings down high white counts and helped 60% of people in a trial.27Blood. A Randomized Trial of Hydroxyurea Versus VP16 in Adult Chronic Myelomonocytic Leukemia Its responses lasted a median of about 2 years.28Blood. A Randomized Trial of Hydroxyurea Versus VP16 in Adult Chronic Myelomonocytic Leukemia It is often used for the high-count type to ease symptoms like an enlarged spleen. Because it is taken by mouth at home, it suits people who find clinic visits tiring. Doses are adjusted using regular blood tests to bring white counts down without pushing other counts too low. It aims more at controlling counts and symptoms than at changing the course of the disease, and if it stops working, doctors may move to azacitidine or another approach.

A donor stem cell transplant is the only treatment that can potentially cure CMML. With lower-risk disease, about 44% were alive 5 years after transplant.29PubMed Central. Allogeneic Hematopoietic Cell Transplant for Adult Chronic Myelomonocytic Leukemia With higher-risk disease, about 19% were alive at 5 years.30PubMed Central. Allogeneic Hematopoietic Cell Transplant for Adult Chronic Myelomonocytic Leukemia Because of its risks, transplant is usually limited to younger or very fit older adults.

In your 60s or 70s, age alone does not rule transplant out; fitness and other illnesses matter more. Timing is often weighed against your risk group. Ask early about donor searches, including siblings.

Risk of Turning Into Acute Leukemia by Age

CMML can change into acute myeloid leukemia (AML), a fast-growing blood cancer, and the chance falls with age:

Younger patients also reached acute leukemia sooner.35PubMed Central. The incidence, risk factors, and survival of acute myeloid leukemia secondary to chronic myelomonocytic leukemia: a population-based study They live longer, giving the disease more time to change, while older people more often die of other causes.

When CMML turns into acute leukemia, immature cells take over the marrow and the disease usually becomes much faster and harder to treat. Treatment may involve intensive chemotherapy or milder drugs, depending on fitness, and it is generally less effective than for AML arising on its own.

Regular blood counts, often every few weeks to months, are the main way a change is spotted, which is why scheduled visits matter even when you feel well. A bone marrow biopsy may be repeated if counts change or symptoms appear, to see if the share of immature cells has crossed the threshold for acute leukemia. Rising blasts, falling platelets or a quickly climbing white count can prompt earlier review.

Rapidly worsening tiredness, fevers or infections, or new bruising or bleeding may signal a change. Report these promptly rather than waiting for the next visit.

Living With CMML Day to Day

In a small group with CMML and related blood cancers, everyone reported fatigue.36Blood. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia Most also had breathlessness, weakness, pain, bruising and dizziness.37Blood. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia Most found walking and household chores harder.38Blood. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia About half avoided things like caring for grandchildren because of infection risk.39Blood. Patient Perspectives on Symptom Experience and Impact on Health-Related Quality of Life in Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myeloid Leukemia

The tiredness comes from anemia, the disease itself and sometimes treatment, so rest does not always fix it. It often fluctuates, so planning important tasks for your best time of day helps. Tell your team how tired you are, because anemia can be treated and some other causes can be addressed too.

A red cell transfusion raises hemoglobin and can ease breathlessness and weakness for a period, often a few weeks. People who need frequent transfusions may eventually build up iron, which the team monitors. Needing transfusions is also information doctors use when judging how the disease is behaving.

Pace activities and keep light movement daily. Ask your team about flu and pneumonia vaccines.

Families can ask about goals of care early, alongside treatment. Palliative care can run alongside active treatment, and clinical trials may be open even to older patients.